Purpose To study the use of intramuscular methylprednisolone in the treatment of cystoid macular oedema in patients with uveitis.
Results After a first injection a significant improvement in vision (an increase of ? 2 Snellen lines) was seen in 15 of 32 eyes (47%), and 17 of 32 eyes (53%) showed no significant change. After the second injection 7 of 17 eyes (41%) showed a significant improvement but there was no change in 9 of 17 eyes (53%). 
Results
After the first injection, 15 of 32 eyes (47%) showed a significant improvement and 17 of 32 eyes (53%) showed no significant change in visual acuity (Fig. 1) . Following a second injection, 7 of 17 eyes (41%) showed a significant improvement, 9 of 17 eyes (53%) no change, but 1 eye (6%) deteriorated more than 2 lines of Snellen acuity (Fig. 2) . The patient whose vision deteriorated had intermediate uveitis and had improved from 6/24 to 6/9 after the first injection but regressed to 6/24 following a second injection for residual macular oedema.
Only 3 patients developed a rise in lOP. In the first patient the lOP rose from 20 to 25 mmHg in the eye not affected with CMO. The second patient had a rise in lOP A retrospective study by Riordan-Eva and Lightman 4 on 54 orbital floor injections to 33 eyes showed a 35% improvement of 2 Snellen lines of acuity. In their patients 7 of 33 eyes had visual acuities of 6/9 or 6/6 before treatment. They found the injections unpredictable. Our patients showed a similar lack of predictability in that failure to achieve significant improvement after the first injection did not predict lack of response to subsequent injections.
It was disappointing that the effects of the injections failed to last more than 3 months in 14 of 22 (64%) 
